|
Solvent |
mg/mL |
mM |
comments |
| Solubility |
| DMF |
30.0 |
122.85 |
|
| DMF:PBS (pH 7.2) (1:2) |
0.3 |
1.23 |
|
| DMSO |
25.0 |
102.36 |
|
| Ethanol |
10.0 |
40.95 |
|
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.
Preparing Stock Solutions
The following data is based on the
product
molecular weight
244.17
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Santes-Palacios R, Olguín-Reyes S, Hernández-Ojeda SL, Camacho-Carranza R, Espinosa-Aguirre JJ. Differential inhibition of naringenin on human and rat cytochrome P450 2E1 activity. Toxicol In Vitro. 2020 Dec;69:105009. doi: 10.1016/j.tiv.2020.105009. Epub 2020 Sep 29. PMID: 33007396.
2: Shah MB, Liu J, Huo L, Zhang Q, Dearing MD, Wilderman PR, Szklarz GD, Stout CD, Halpert JR. Structure-Function Analysis of Mammalian CYP2B Enzymes Using 7-Substituted Coumarin Derivatives as Probes: Utility of Crystal Structures and Molecular Modeling in Understanding Xenobiotic Metabolism. Mol Pharmacol. 2016 Apr;89(4):435-45. doi: 10.1124/mol.115.102111. Epub 2016 Jan 29. PMID: 26826176; PMCID: PMC4809303.
3: Mooiman KD, Goey AK, Huijbregts TJ, Maas-Bakker RF, Beijnen JH, Schellens JH, Meijerman I. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. J Pharm Pharmacol. 2014 Sep;66(9):1339-46. doi: 10.1111/jphp.12259. Epub 2014 Apr 15. PMID: 24730468.
4: Wilderman PR, Gay SC, Jang HH, Zhang Q, Stout CD, Halpert JR. Investigation by site-directed mutagenesis of the role of cytochrome P450 2B4 non-active-site residues in protein-ligand interactions based on crystal structures of the ligand-bound enzyme. FEBS J. 2012 May;279(9):1607-20. doi: 10.1111/j.1742-4658.2011.08411.x. Epub 2011 Nov 25. PMID: 22051155; PMCID: PMC3911823.
5: Makaji E, Trambitas CS, Shen P, Holloway AC, Crankshaw DJ. Effects of cytochrome P450 inhibitors on the biotransformation of fluorogenic substrates by adult male rat liver microsomes and cDNA-expressed rat cytochrome P450 isoforms. Toxicol Sci. 2010 Feb;113(2):293-304. doi: 10.1093/toxsci/kfp255. Epub 2009 Oct 25. PMID: 19858067.
6: Oezguen N, Kumar S, Hindupur A, Braun W, Muralidhara BK, Halpert JR. Identification and analysis of conserved sequence motifs in cytochrome P450 family 2. Functional and structural role of a motif 187RFDYKD192 in CYP2B enzymes. J Biol Chem. 2008 Aug 1;283(31):21808-16. doi: 10.1074/jbc.M708582200. Epub 2008 May 21. PMID: 18495666; PMCID: PMC2490781.
7: Szotáková B, Baliharová V, Lamka J, Nozinová E, Wsól V, Velík J, Machala M, Neca J, Soucek P, Susová S, Skálová L. Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. Res Vet Sci. 2004 Feb;76(1):43-51. doi: 10.1016/s0034-5288(03)00143-7. PMID: 14659728.
8: Egnell AC, Eriksson C, Albertson N, Houston B, Boyer S. Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther. 2003 Dec;307(3):878-87. doi: 10.1124/jpet.103.054999. Epub 2003 Oct 13. PMID: 14557374.
